Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
He XX, Wu XL, Chen RP, Chen C, Liu XG, Wu BJ, Huang ZM
PloS one · 84 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2016-10-06 · PLoS One · vol. 11 · número 10 · pág. e0162368
- Editorial
- Public Library of Science
- Citado
- 129 citas · más que el 89% de estudios similares · 2.3× el promedio de su campo
- Referencias
- 58 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Liver Disease Diagnosis and Treatment · Fatty Acid Research and Health · Alcohol Consumption and Health Effects
- Palabras clave
- omega-3 polyunsaturated fatty acids, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, alanine aminotransferase, aspartate aminotransferase, triglycerides, total cholesterol, HDL cholesterol, liver fibrosis, hepatocellular carcinoma, lipid metabolism, liver enzymes, dietary supplementation, treatment effectiveness, safety and tolerability
- MeSH
- humans, blood glucose, lipids, fatty acids, omega-3, fasting, randomized controlled trials as topic, non-alcoholic fatty liver disease
7 autores
- Xixi He🇨🇳First Affiliated Hospital of Wenzhou Medical University
- Xiaoli Wu🇨🇳First Affiliated Hospital of Wenzhou Medical University
- Renpin Chen🇨🇳First Affiliated Hospital of Wenzhou Medical University
- Chao Chen🇨🇳First Affiliated Hospital of Wenzhou Medical University
- Xiaogang Liu🇨🇳Ningxia Hui Autonomous Region Peoples Hospital
- Bin-Jiao Wu🇨🇳Yueqing People's Hospital
- Zhiming Huang🇨🇳 · autor de correspondenciaFirst Affiliated Hospital of Wenzhou Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Non-alcoholic fatty liver disease (NAFLD) is a clinical syndrome with the main characteristic of diffuse liver cells with fatty changes. The clinical evolution of NAFLD includes simple non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH), liver fibrosis and cirrhosis, and even hepatocellular carcinoma.
Methods and findings
We conducted this review to identify the effectiveness of omega-3 polyunsaturated fatty acids (ω-3 PUFA) in NAFLD. We searched PubMed, Cochrane Library and Embase. All randomized controlled trials (RCTs) of ω-3 PUFA treatment for NAFLD were considered. Two reviewers assessed the quality of each study and collected data independently. Disagreements were resolved by discussion among the reviewers and any of the other authors of the paper. We performed a meta-analysis and reported summary estimates of outcomes as inverse variance (IV), fixed or random, with 95% confidence intervals (CIs). We included seven RCTs involving 442 patients (227 for the experimental group and 215 for the control group). All the patients were divided into two groups: one treated with ω-3 PUFA and the other was the control group (generally placebo). The demographics of the ω-3 PUFA and control groups were comparable. Beneficial changes in alanine aminotransferase (ALT) (IV 95% CI: -7.61 [-12.83 to -2.39], p = 0.004), total cholesterol (TC) (IV 95% CI: -13.41 [-21.44 to -5.38], p = 0.001), triglyceride (TG) (IV 95% CI: -43.96 [-51.21 to -36.71], p<0.00001) and high-density lipoprotein cholesterol (HDL-C) (IV 95% CI: 6.97 [2.05 to 11.90], p = 0.006) favored ω-3 PUFA treatment. Omega-3 PUFA tended towards a beneficial effect on aspartate aminotransferase (AST) (IV 95% CI: -6.89 [-17.71 to 3.92], p = 0.21), γ-glutamyl transferase (GGT) (IV 95% CI: -8.28 [-18.38 to 1.83], p = 0.11) and low-density lipoprotein cholesterol (LDL-C) (IV 95% CI: -7.13 [-14.26 to 0.0], p = 0.05).
Conclusions
Supplementation with ω-3 PUFA is a practical and effective treatment for NAFLD to decrease ALT, TC and increase HDL-C, especially to decrease TG. Omega-3 PUFA also has a tendency toward a beneficial effect on AST, GGT and LDL-C. More high-quality, large RCTs are needed to validate our findings.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.